Latest News and Press Releases

Til NASDAQ OMX Copenhagen A/S Investor Nyhed nr. 08-13 / København, 30. august 2013 Topotarget skal præsentere på 15th Annual Rodman & Renshaw Global Investment Conference, som afholdes i...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 22-13 / København, 28. august 2013 Topotarget meddeler hermed, at den første patient har fået dosis i studiet til fastsættelse af dosis af belinostat...

To NASDAQ OMX Copenhagen A/S Announcement no. 22-13 / Copenhagen, August 28, 2013 Topotarget announces that the first patient has been dosed in the dose-finding study of belinostat in...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 21-13 / København, 14. august 2013 Topotarget meddeler, at bestyrelsen i dag har behandlet og godkendt selskabets delårsrapport for perioden 1....

To NASDAQ OMX Copenhagen A/S Announcement no. 21-13 / Copenhagen, August 14, 2013 Topotarget announces that the board of directors has reviewed and approved the company’s interim report for the...

To NASDAQ OMX Copenhagen A/S Announcement no. 20-13 / Copenhagen, August 8, 2013 On August 7, 2013, Spectrum Pharmaceuticals announced that the filing of the New Drug Application (NDA) for...

Til NASDAQ OMX Copenhagen A/S Meddelelse nr. 20-13 / København, 8. august 2013 Den 7. august 2013 offentliggjorde Spectrum Pharmaceuticals, at indleveringen af registreringsansøgningen (NDA) for...

To NASDAQ OMX Copenhagen A/S Investor News No. 07-13 / Copenhagen, August 6, 2013 Topotarget announces that a teleconference will be held on August 14, 2013 at 1:00 pm CET. CEO Anders Vadsholt...

Til NASDAQ OMX Copenhagen A/S Investor Nyhed nr. 07-13 / København, 6. august 2013 Topotarget meddelte i dag, at der vil blive afholdt en telefonkonference den 14. august 2013 kl. 13.00 dansk...

To NASDAQ OMX Copenhagen A/S Announcement no. 19-13 / Copenhagen, July 18, 2013   On July 17, 2013, the European Commission granted Topotarget an orphan drug designation for belinostat...